The demonstration of the in vivo effect of this PROTAC is promising for lung cancer patients with KRAS mutations, as chemicals targeting SOS1-based therapy are currently the subject of ongoing clinical trials [32]. This evidence concerns the gene KRAS and lung carcinoma.